rawpixel-shutterstock-com-4-1
Rawpixel / Shutterstock.com
29 October 2015AmericasCatherine Coombes

CRISPR: careless talk costs patents

The identification of the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system for gene editing of eukaryotes has led to an explosion of research in this area due to the far-reaching applications of the system. This in turn has led to a race to carve out valuable commercial protection for CRISPR/Cas9 and use of this system in various applications.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
6 February 2026   A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.
Americas
3 February 2026   Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.
Americas
29 January 2026   A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.